Sacubitril
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril]. | Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril]. | ||
| - | <scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH | + | Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.[2] Sacubitrilat inhibits the enzyme neprilysin,[3] which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure–lowering peptides that work mainly by reducing blood volume.[4] |
| + | |||
| + | <scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH Sacubitrilat</scene> ([[5jmy]]). | ||
<scene name='10/1001143/Binding_site/1'>Sacubitrilat binding site</scene>. Water molecules are shown as red spheres. | <scene name='10/1001143/Binding_site/1'>Sacubitrilat binding site</scene>. Water molecules are shown as red spheres. | ||
Revision as of 09:56, 16 October 2023
| |||||||||||
